| Description | Perlapine is an effective and selective HM3DQ DREADD agonist (EC50 = 2.8 nM). |
| molecular weight | 291.39 |
| Molecular formula | C19H21N3 |
| CAS | 1977-11-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Meltzer HY, Fessler RG, Fang VS. Perlapine: relationship between stimulation of prolactin secretion and antipsychotic activity. Psychopharmacology (Berl). 1977 Oct 20;54(2):183-6. PubMed PMID: 412213. 2. Wilk S, Stanley M. Perlapine and dopamine metabolism: prediction of antipsychotic efficacy. Eur J Pharmacol. 1977 Jan 7;41(1):65-72. PubMed PMID: 12986. 3. Bürki HR, Ruch W, Asper H. Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacologia. 1975;41(1):27-33. PubMed PMID: 235767. 4. Allen SR, Oswald I. The effects of perlapine on sleep. Psychopharmacologia. 1973 Aug 22;32(1):1-9. PubMed PMID: 4359662. |